First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors Authors: L.L. Siu, M.E. Gutierrez, L. Pudelko, K. Ruth, M.A.F.N. Filho, R. Zaynagetdinov, P. Hu, T. Kitzing, B.K. Guenhan, I. Durutovic, M. McKean Published: 2026 ABSTRACT BackgroundAdenosine is a key driver of an immunosuppressive tumor microenvironment. Elevated extracellular adenosine levels in the tumor microenvironment contribute to therapeutic resistance via A2A and A2B adenosine receptor signaling on T cells. Dual A2A/A2B antagonism may provide a therapeutic advantage compared with selective inhibition of either receptor alone. Muvadenant (M1069), a small molecule dual antagonist of A2A and A2B receptors, showed encouraging preclinical activity.Patients and methodsThis phase I, open-label, first-in-human study (NCT05198349) evaluated muvadenant in adult patients with advanced solid malignancies (Eastern Cooperative Oncology Group performance status ≤1). Primary objectives were determination of maximum tolerated dose and recommended dose for expansion of muvadenant. Additional objectives included pharmacokinetics, pharmacodynamics and early signs of efficacy.ResultsOverall, 15 patients were evaluated across four dose levels (DLs) of muvadenant monotherapy provided twice daily (bd): 150 mg (n = 3), 300 mg (n = 3), 450 mg (n = 6), and 600 mg (n = 3). Dose-limiting toxicities were reported in two patients [grade 4 blood creatinine phosphokinase increased (450-mg DL, n = 1) and grade 3 lipase increased (600-mg DL, n = 1)]. Fatigue and nausea were the most common adverse events (n = 5 each, 33.3% each), while nausea was the most common muvadenant-related adverse event (n = 4, 26.7%). Two deaths were reported, both attributed to disease progression >30 days after treatment end. Best overall response of stable disease was recorded in three patients, including one patient with a stable disease of 12.6 months at the 150-mg DL. Median progression-free survival was 1.3 months (95% confidence interval 1.2-2.6). The potential recommended dose for expansion was 450-mg bd, and the maximum tolerated dose was not established due to early closure of the study.ConclusionsMuvadenant was generally well tolerated; however, no antitumor activity was observed. A potential dose–response could not be determined due to limited number of patients per DL. Introduction Immune checkpoint inhibitors (ICIs) have shown durable clinical responses in several solid and hematological malignancies by enhancing antitumor immunity, primarily through the blockade of the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 axis.1,2 However, a substantial proportion of patients do not derive benefit from ICIs, with response rates being <20% in certain tumor types, suggesting a role for other immunosuppressive pathways in the tumor microenvironment (TME).2, 3, 4 Acquired resistance to ICIs may also limit their durable therapeutic responses.5,6 Adenosine, an immunosuppressive cytokine, contributes to this acquired resistance to ICIs by inhibiting effector T cells and promoting the expansion of Tregs.7, 8, 9 Within the hypoxic TME, extracellular ATP from dying and metabolically stressed cells is converted into adenosine through the CD39–CD73 enzymatic cascade, with CD73 catalyzing the final step.10,11 Extracellular adenosine signaling occurs through a set of four G protein–coupled receptors: A1, A2A, A2B and A3.1 Of these, A2A and A2B receptors (A2AR and A2BR) are co-expressed on many different cell types, including tumor cells, immune cells and endothelial cells.12 The binding of adenosine to its receptors results in an intracellular buildup of cyclic adenosine monophosphate (cAMP), which then stifles T-cell–mediated antitumor responses.7,13,14 In effect, adenosine has a dampening effect on the immune response and is a key driver of an immunosuppressive TME.7,14,15 Additionally, the expression and relative proportion of A2A and A2B receptors can markedly increase under pathological conditions.12 Therefore, A2AR and A2BR are attractive therapeutic targets. Although available in vitro and in vivo preclinical data support the development and clinical testing of therapeutic agents that target either A2A16,17 or A2B18 receptors individually, dual A2A/A2B antagonism may provide greater therapeutic potential because these two receptors modulate each other’s activity12,19 and stimulate adenosine-driven tumor growth through stimulatory G protein–mediated cAMP accumulation shared by both receptors.20 Furthermore, A2B can also promote tumor growth through A2A-independent mechanisms via the Gq subunit of G protein–coupled receptors.21 Emerging preclinical data indicate that a combination of ICIs and adenosine signaling blocking agents can result in enhanced antitumor responses and reduced growth of tumors and metastases in mice.15,22 Thus, suppression of both A2A and A2B receptors, either alone or in combination with other therapeutic modalities, such as ICIs, radiation or chemotherapies that promote hypoxia and cell death within the TME,13 represents a promising treatment approach. Muvadenant (M1069) is an orally administered, highly selective, small molecule dual antagonist of A2AR and A2BR with preclinical antitumor activity both as monotherapy and in combination with immunotherapies or chemotherapies in CD73-high and/or adenosine-rich TMEs.15,23 This first-in-human study evaluated muvadenant monotherapy in patients with metastatic or locally advanced unresectable solid tumors.24 Patients and methods Study design This phase I, open-label, sequential dose-escalation study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of muvadenant monotherapy in patients with advanced solid malignancies at three centers in the United States and Canada (NCT05198349). Muvadenant was provided orally, twice daily (bd), and food intake was restricted for 2 hours before and 1 hour after dose administration. Detailed study design is presented in Supplementary Figure S1 (available at https://doi.org/10.1016/j.esmoop.2026.106962). Adult patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1 who had been diagnosed with locally advanced or metastatic disease that was refractory to or had progressed with standard therapy, with adequate hematological, renal and hepatic function were included in the study. Only patients who met specific ophthalmological criteria (such as predefined best-corrected visual acuity and normal optical coherence tomography) were included. This decision was based on the observation of minimal to mild, dose-unrelated and fully reversible retinal alterations in albino rats after 4 weeks of muvadenant treatment. Patients with a history of eye diseases affecting the eye in such a way that progressive change of visual function or ocular structures was expected within the study duration, prior treatment with another agent targeting the adenosine signaling pathway or prior anticancer treatment within 4 weeks or 5 half-lives were excluded. Detailed inclusion and exclusion criteria are provided in the Supplementary Material (available at https://doi.org/10.1016/j.esmoop.2026.106962). The study included a 28-day screening period, a study intervention period of consecutive 21-day cycles, a dose-limiting toxicity (DLT) observation period of 21 days, an end-of-study visit (within 7 days from decision to stop muvadenant therapy) and a safety follow-up period of 30 ± 7 days after the last muvadenant dose. Patients continued study intervention until disease progression, unacceptable toxicity, withdrawal of consent or until criteria for study discontinuation were met. Detailed discontinuation criteria are provided as part of the Supplementary Material (available at https://doi.org/10.1016/j.esmoop.2026.106962). Patients who discontinued study intervention for any reason completed an end-of-study visit. Objectives and assessments The primary objectives of this study were to determine the dose–toxicity relationship [maximum tolerated dose (MTD), if reached] of muvadenant monotherapy in patients with advanced solid tumors and the recommended dose for expansion (RDE) for further exploratory clinical development. The dose–toxicity relationship was assessed based on occurrence of DLTs (see the Supplementary Material for a detailed definition, available at https://doi.org/10.1016/j.esmoop.2026.106962), adverse events (AEs) and treatment-related AEs (TRAEs). AEs of special interest (AESIs) for this study included a decrease in visual acuity of >15 letters in Early Treatment Diabetic Retinopathy Study chart, which is a standardized visual acuity chart that uses the logarithm of the minimum angle of resolution scale for more precise assessment and quantification of visual acuity compared with traditional charts.25,26 Other AESIs included loss of mean deviation in static visual field of >3.5 dB and the emergence of distinct retinal signs or abnormal findings in optical coherence tomography. The final RDE was to be based on the totality of safety, tolerability, PK and PD data. Secondary objectives included characterization of the PK profile and clinical activity of muvadenant; the latter was evaluated based on objective response, duration of response (DoR) and progression-free survival (PFS), all according to RECIST v1.1 (per investigator). End points were analyzed regardless of whether or not the following intercurrent events had occurred, namely, discontinuation of treatment and start of subsequent anticancer therapy. The Safety Monitoring Committee (SMC) provided recommendations on the dose level (DL) and regimen for the next cohort, as well as with decision(s) regarding exclusion of patients from the DLT analysis, as needed. Objective response was defined as the proportion of patients with a confirmed objective response of partial response (PR) or complete response (CR). Confirmation of response according to RECIST v1.1 was required no sooner than 6 weeks after the initial documentation of CR or PR. Stable disease (SD) was defined as at least one SD assessment (or better) at ≥6 weeks after treatment initiation (and not qualifying for CR or PR). DoR was defined for patients with an objective response, as the time (in months) from first documentation of objective response (CR or PR) to the date of first documentation of progressive disease or death due to any cause, whichever occurred first. PFS was defined as the time from first study intervention to progressive disease or death. Both DoR and PFS were estimated using the Kaplan–Meier method. Events were considered only if they occurred within two scheduled tumor assessments after last evaluable assessment or start of treatment. Samples for PK and PD analyses were collected at scheduled visits throughout the study. Detailed methodology for primary and secondary end points is provided in the Supplementary Material (available at https://doi.org/10.1016/j.esmoop.2026.106962). Statistical analyses Descriptive statistics were used to summarize study data. Unless otherwise specified, all analyses were based on the safety analysis set that included all patients who had received at least one dose of study intervention. All patients who received muvadenant were included in the safety, PK and PD analysis sets. The DLT analysis set included patients who had received ≥80% of the planned cumulative dose during the DLT period. A Bayesian 2-parameter logistic regression model (BLRM) was applied to assist the SMC in dosing recommendations.27 The target DLT probability for the MTD suggested by the BLRM was 30%. A potential RDE DL was to be selected based on the data of ≥3 patients. At this DL, two additional confirmatory cohorts with three patients each could be enrolled (per SMC decision). For these additional cohorts, mandatory paired pretreatment and on-treatment biopsies were planned to be collected. The final RDE was to be based on all available safety, tolerability, PK, PD and post-treatment changes in TME from paired tumor biopsies. The RDE was described as a safe dose of muvadenant where ∼90% inhibition of phosphorylated cAMP response element–binding protein (pCREB, a PD biomarker reflecting downstream activity of the A2AR) was reached at trough concentration of steady state (Cmin, ss), in ex vivo stimulated blood. To ensure the coverage of both A2A and A2B receptors with muvadenant in this study, we extrapolated IC50 (concentration that causes 50% inhibition of growth) values for muvadenant on A2A and A2B receptors from our in vitro studies with primary human T cells and myeloid cells to the steady-state free plasma concentration of muvadenant obtained from this first-in-human study. The RDE could not exceed the MTD. The sample size for the RDE and the MTD DLs needed to be at least six. No formal statistical hypotheses were tested and all analyses are considered descriptive. For the Bayesian computations, the crmPack R package (version 1.0.6) was used.28 All analyses were carried out using statistical software SAS, R software and the R package bcrm (version 1.0.6).28 Results Patients and exposure From 3 March 2022 to 9 May 2023, a total of 15 patients were enrolled and treated across four DLs of muvadenant: 150 mg (n = 3), 300 mg (n = 3), 450 mg (n = 6) and 600 mg (n = 3). Table 1 provides an overview of the baseline and demographic characteristics. Briefly, the majority of patients were men (53.3%), the median age was 61.0 years and two-thirds (66.7%) were <65 years of age. All patients had stage IV disease, with considerable heterogeneity in primary tumor types. Four patients (26.7%) had received prior ICI therapy. Overall, the median duration of muvadenant therapy was 6.1 weeks (range 2-55 weeks) and the median number of doses administered was 84 (range 21-739). Of the 15 patients treated, only 13 received between 90% and 110% of their target dose intensity.Table 1Demographic and baseline characteristicsCharacteristicMuvadenant monotherapy (bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Sex Female1 (33.3)3 (100.0)2 (33.3)1 (33.3)7 (46.7) Male2 (66.7)0 (0.0)4 (66.7)2 (66.7)8 (53.3)Race Asian0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Black or African American1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7) White2 (66.7)3 (100.0)5 (83.3)3 (100.0)13 (86.7)Age categories <65 years2 (66.7)2 (66.7)4 (66.7)2 (66.7)10 (66.7) ≥65 years1 (33.3)1 (33.3)2 (33.3)1 (33.3)5 (33.3)BMI (kg/m2)BMI (Kg/m2), mean ± SD26.32 ± NC24.88 ± NC27.59 ± 13.4529.23 ± NC27.12 ± 8.90ECOG PSa 02 (66.7)1 (33.3)1 (16.7)1 (33.3)5 (33.3) 11 (33.3)2 (66.7)5 (83.3)2 (66.7)10 (66.7)Primary tumor locationb Colon0 (0.0)0 (0.0)2 (33.3)1 (33.3)3 (20.0) Pancreas1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3) Leiomyosarcoma1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3)No. of prior anticancer drug therapy regimens for metastatic/locally advanced diseasec 11 (33.3)1 (33.3)0 (0.0)0 (0.0)2 (13.3) 21 (33.3)0 (0.0)2 (33.3)2 (66.7)5 (33.3) 30 (0.0)1 (33.3)1 (16.7)1 (33.3)3 (20.0) ≥41 (33.3)0 (0.0)2 (33.3)0 (0.0)3 (20.0)Values are n (%) unless specified.bd, twice daily; BMI, body mass index; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group performance status; NC, not calculated.aECOG PS = 0: fully active, able to carry on all predisease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out light or sedentary work (e.g. light housework and office work).bTable lists only primary tumor locations with more than one patient. Tumor types reported in only one patient each include adenoid cystic carcinoma (left parotid gland), ampullary adenocarcinoma, clear cell sarcoma, duodenal adenocarcinoma, left thigh sarcoma, ovarian cancer, thymic tumor and urothelial carcinoma.cOverall, four patients had received prior treatment with immune checkpoint inhibitors (150-mg DL, n = 1; 450-mg DL, n = 3). Table 1Demographic and baseline characteristicsCharacteristicMuvadenant monotherapy (bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Sex Female1 (33.3)3 (100.0)2 (33.3)1 (33.3)7 (46.7) Male2 (66.7)0 (0.0)4 (66.7)2 (66.7)8 (53.3)Race Asian0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Black or African American1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7) White2 (66.7)3 (100.0)5 (83.3)3 (100.0)13 (86.7)Age categories <65 years2 (66.7)2 (66.7)4 (66.7)2 (66.7)10 (66.7) ≥65 years1 (33.3)1 (33.3)2 (33.3)1 (33.3)5 (33.3)BMI (kg/m2)BMI (Kg/m2), mean ± SD26.32 ± NC24.88 ± NC27.59 ± 13.4529.23 ± NC27.12 ± 8.90ECOG PSa 02 (66.7)1 (33.3)1 (16.7)1 (33.3)5 (33.3) 11 (33.3)2 (66.7)5 (83.3)2 (66.7)10 (66.7)Primary tumor locationb Colon0 (0.0)0 (0.0)2 (33.3)1 (33.3)3 (20.0) Pancreas1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3) Leiomyosarcoma1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3)No. of prior anticancer drug therapy regimens for metastatic/locally advanced diseasec 11 (33.3)1 (33.3)0 (0.0)0 (0.0)2 (13.3) 21 (33.3)0 (0.0)2 (33.3)2 (66.7)5 (33.3) 30 (0.0)1 (33.3)1 (16.7)1 (33.3)3 (20.0) ≥41 (33.3)0 (0.0)2 (33.3)0 (0.0)3 (20.0)Values are n (%) unless specified.bd, twice daily; BMI, body mass index; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group performance status; NC, not calculated.aECOG PS = 0: fully active, able to carry on all predisease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out light or sedentary work (e.g. light housework and office work).bTable lists only primary tumor locations with more than one patient. Tumor types reported in only one patient each include adenoid cystic carcinoma (left parotid gland), ampullary adenocarcinoma, clear cell sarcoma, duodenal adenocarcinoma, left thigh sarcoma, ovarian cancer, thymic tumor and urothelial carcinoma.cOverall, four patients had received prior treatment with immune checkpoint inhibitors (150-mg DL, n = 1; 450-mg DL, n = 3). Demographic and baseline characteristics Values are n (%) unless specified. bd, twice daily; BMI, body mass index; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group performance status; NC, not calculated. ECOG PS = 0: fully active, able to carry on all predisease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out light or sedentary work (e.g. light housework and office work). Table lists only primary tumor locations with more than one patient. Tumor types reported in only one patient each include adenoid cystic carcinoma (left parotid gland), ampullary adenocarcinoma, clear cell sarcoma, duodenal adenocarcinoma, left thigh sarcoma, ovarian cancer, thymic tumor and urothelial carcinoma. Overall, four patients had received prior treatment with immune checkpoint inhibitors (150-mg DL, n = 1; 450-mg DL, n = 3). Tolerability and safety An overview of the safety profile is provided in Table 2. Changes in hematology and biochemistry parameters were not suggestive of general hematological, hepatic or renal toxicity. No treatment-emergent AEs (TEAEs) led to death during the study.Table 2Safety overviewAE typeMuvadenant monotherapy (oral, bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Any TEAEa3 (100.0)3 (100.0)6 (100.0)2 (66.7)14 (93.3)Any grade ≥3 TEAEb1 (33.3)2 (66.7)2 (33.3)2 (66.7)7 (46.7)Any grade ≥4 TEAEb0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)Any muvadenant-related TEAEc2 (66.7)3 (100.0)4 (66.7)1 (33.3)10 (66.7)Any muvadenant-related grade ≥3 TEAEb,c0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3)Any muvadenant-related grade ≥4 TEAEb,c0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)Any serious TEAE1 (33.3)2 (66.7)0 (0.0)0 (0.0)3 (20.0)Any muvadenant-related serious TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)TEAE leading to permanent discontinuation of muvadenantd0 (0.0)0 (0.0)0 (0.0)1 (33.3)1 (6.7)TEAE leading to dose reduction of muvadenant0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)TEAE leading to dose interruption of muvadenant1 (33.3)1 (33.3)2 (33.3)0 (0.0)4 (26.7)Any TEAE leading to death0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Any related TEAE leading to death0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Values are n (%).AE, adverse event; bd, twice daily; TEAE, treatment-emergent adverse event.aTEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment).bSeverity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.cRelated TEAEs were those reported as having a relationship of yes or missing.dTEAEs leading to permanent discontinuation were events recorded with the action drug withdrawn on the electronic case report form page. Table 2Safety overviewAE typeMuvadenant monotherapy (oral, bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Any TEAEa3 (100.0)3 (100.0)6 (100.0)2 (66.7)14 (93.3)Any grade ≥3 TEAEb1 (33.3)2 (66.7)2 (33.3)2 (66.7)7 (46.7)Any grade ≥4 TEAEb0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)Any muvadenant-related TEAEc2 (66.7)3 (100.0)4 (66.7)1 (33.3)10 (66.7)Any muvadenant-related grade ≥3 TEAEb,c0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3)Any muvadenant-related grade ≥4 TEAEb,c0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)Any serious TEAE1 (33.3)2 (66.7)0 (0.0)0 (0.0)3 (20.0)Any muvadenant-related serious TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)TEAE leading to permanent discontinuation of muvadenantd0 (0.0)0 (0.0)0 (0.0)1 (33.3)1 (6.7)TEAE leading to dose reduction of muvadenant0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)TEAE leading to dose interruption of muvadenant1 (33.3)1 (33.3)2 (33.3)0 (0.0)4 (26.7)Any TEAE leading to death0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Any related TEAE leading to death0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Values are n (%).AE, adverse event; bd, twice daily; TEAE, treatment-emergent adverse event.aTEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment).bSeverity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.cRelated TEAEs were those reported as having a relationship of yes or missing.dTEAEs leading to permanent discontinuation were events recorded with the action drug withdrawn on the electronic case report form page. Safety overview Values are n (%). AE, adverse event; bd, twice daily; TEAE, treatment-emergent adverse event. TEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment). Severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Related TEAEs were those reported as having a relationship of yes or missing. TEAEs leading to permanent discontinuation were events recorded with the action drug withdrawn on the electronic case report form page. Among DLT-assessable patients (150-mg DL, n = 3; 300-mg DL, n = 2; 450-mg DL, n = 5; 600-mg DL, n = 3), DLTs were reported in two patients: grade 4 blood creatinine phosphokinase increased (450 mg DL, n = 1) and grade 3 lipase increased (600-mg DL, n = 1) (Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2026.106962). Both DLT events were nonserious and considered related to muvadenant. Two patients were confirmed as not DLT evaluable by the SMC (1 patient each in the 300-mg and 450-mg DLs) as 80% of planned dose was not administered. Fatigue and nausea were the most common TEAEs reported across DLs (n = 5 each, 33.3% each), followed by muscle spasm and vomiting (n = 3 each, 20.0%); no other TEAEs were reported in ≥3 patients (20.0%) across the DLs tested (Table 3). Grade ≥3 TEAEs were observed in seven patients and included one grade 4 event of blood creatinine phosphokinase increased. There were no grade 5 TEAEs, and none of the grade ≥3 TEAEs were observed in more than one patient (Table 3).Table 3Frequently reported TEAEs (≥10% of patients overall)System organ class preferred termMuvadenant monotherapy (oral, bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3Patients with ≥1 TEAEs3 (100.0)1 (33.3)3 (100.0)2 (66.7)6 (100.0)2 (33.3)2 (66.7)2 (66.7)14 (93.3)7 (46.7)Blood and lymphatic system disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)1 (16.7)0 (0.0)0 (0.0)2 (13.3)1 (6.7) Anemia1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)1 (16.7)0 (0.0)0 (0.0)2 (13.3)1 (6.7)Eye disorders2 (66.7)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Retinal degeneration2 (66.7)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Gastrointestinal disorders2 (66.7)0 (0.0)3 (100.0)1 (33.3)2 (33.3)0 (0.0)2 (66.7)0 (0.0)9 (60.0)1 (6.7) Nausea1 (33.3)0 (0.0)2 (66.7)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)5 (33.3)0 (0.0) Vomiting1 (33.3)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Abdominal pain1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Constipation0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Diarrhea0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Stomatitis0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Retroperitoneal hemorrhage0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)General disorders and administration site conditions2 (66.7)0 (0.0)1 (33.3)0 (0.0)3 (50.0)0 (0.0)2 (66.7)0 (0.0)8 (53.3)0 (0.0) Fatigue1 (33.3)0 (0.0)1 (33.3)0 (0.0)2 (33.3)0 (0.0)1 (33.3)0 (0.0)5 (33.3)0 (0.0) Pyrexia0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0)Infections and infestations0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (33.3)0 (0.0)0 (0.0)0 (0.0)3 (20.0)0 (0.0) Urinary tract infection0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Investigations0 (0.0)0 (0.0)0 (0.0)0 (0.0)3 (50.0)1 (16.7)2 (66.7)1 (33.3)5 (33.3)2 (13.3) Lipase increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)1 (33.3)2 (13.3)1 (6.7) Amylase increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Blood CPK increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Metabolism and nutrition disorder0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (33.3)0 (0.0)2 (66.7)1 (33.3)4 (26.7)1 (6.7) Hypokalemia0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)1 (33.3)2 (13.3)1 (6.7)Musculoskeletal and connective tissue disorders1 (33.3)0 (0.0)2 (66.7)1 (33.3)2 (33.3)0 (0.0)1 (33.3)0 (0.0)6 (40.0)1 (6.7) Muscle spasm0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Pain in extremity0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Groin pain0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Nervous system disorders0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7) Cerebrovascular accident0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Respiratory, thoracic and mediastinal disorders0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Oropharyngeal pain0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0)Skin and subcutaneous tissue disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Pruritus1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Values are n (%).bd, twice daily; CPK, creatinine phosphokinase; TEAE, treatment-emergent adverse event. Table 3Frequently reported TEAEs (≥10% of patients overall)System organ class preferred termMuvadenant monotherapy (oral, bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3AllGrade ≥ 3Patients with ≥1 TEAEs3 (100.0)1 (33.3)3 (100.0)2 (66.7)6 (100.0)2 (33.3)2 (66.7)2 (66.7)14 (93.3)7 (46.7)Blood and lymphatic system disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)1 (16.7)0 (0.0)0 (0.0)2 (13.3)1 (6.7) Anemia1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)1 (16.7)0 (0.0)0 (0.0)2 (13.3)1 (6.7)Eye disorders2 (66.7)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Retinal degeneration2 (66.7)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Gastrointestinal disorders2 (66.7)0 (0.0)3 (100.0)1 (33.3)2 (33.3)0 (0.0)2 (66.7)0 (0.0)9 (60.0)1 (6.7) Nausea1 (33.3)0 (0.0)2 (66.7)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)5 (33.3)0 (0.0) Vomiting1 (33.3)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Abdominal pain1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Constipation0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Diarrhea0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Stomatitis0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Retroperitoneal hemorrhage0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)General disorders and administration site conditions2 (66.7)0 (0.0)1 (33.3)0 (0.0)3 (50.0)0 (0.0)2 (66.7)0 (0.0)8 (53.3)0 (0.0) Fatigue1 (33.3)0 (0.0)1 (33.3)0 (0.0)2 (33.3)0 (0.0)1 (33.3)0 (0.0)5 (33.3)0 (0.0) Pyrexia0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0)Infections and infestations0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (33.3)0 (0.0)0 (0.0)0 (0.0)3 (20.0)0 (0.0) Urinary tract infection0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Investigations0 (0.0)0 (0.0)0 (0.0)0 (0.0)3 (50.0)1 (16.7)2 (66.7)1 (33.3)5 (33.3)2 (13.3) Lipase increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)1 (33.3)2 (13.3)1 (6.7) Amylase increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Blood CPK increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Metabolism and nutrition disorder0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (33.3)0 (0.0)2 (66.7)1 (33.3)4 (26.7)1 (6.7) Hypokalemia0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (33.3)1 (33.3)2 (13.3)1 (6.7)Musculoskeletal and connective tissue disorders1 (33.3)0 (0.0)2 (66.7)1 (33.3)2 (33.3)0 (0.0)1 (33.3)0 (0.0)6 (40.0)1 (6.7) Muscle spasm0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Pain in extremity0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0) Groin pain0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Nervous system disorders0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7) Cerebrovascular accident0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Respiratory, thoracic and mediastinal disorders0 (0.0)0 (0.0)1 (33.3)0 (0.0)1 (16.7)0 (0.0)1 (33.3)0 (0.0)3 (20.0)0 (0.0) Oropharyngeal pain0 (0.0)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2 (13.3)0 (0.0)Skin and subcutaneous tissue disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0) Pruritus1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (16.7)0 (0.0)0 (0.0)0 (0.0)2 (13.3)0 (0.0)Values are n (%).bd, twice daily; CPK, creatinine phosphokinase; TEAE, treatment-emergent adverse event. Frequently reported TEAEs (≥10% of patients overall) Values are n (%). bd, twice daily; CPK, creatinine phosphokinase; TEAE, treatment-emergent adverse event. Overall, muvadenant-related TEAEs (TRAEs) were reported in 10 patients (66.7%). Nausea was the most common TRAE (n = 4, 26.7%), followed by abdominal pain, lipase increased and pruritus (n = 2, 13.3%); no other TRAEs were reported in more than one patient (Table 4). Only two grade ≥3 TRAEs were reported, and both events were assessed to be DLTs. Notably, the patient in the 600-mg DL had a concurring grade 1 amylase increased event, along with symptomatic grade 3 lipase increased (DLT) with abdominal pain, pyrexia and nausea (all grade 2).Table 4Muvadenant-related TEAEsSystem organ class preferred termaMuvadenant monotherapy (bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Patients with ≥1 muvadenant-related TEAEb2 (66.7)3 (100.0)4 (66.7)1 (33.3)10 (66.7)Eye disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7) Retinal degeneration1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Gastrointestinal disorders1 (33.3)3 (100.0)1 (16.7)1 (33.3)6 (40.0) Nausea0 (0.0)2 (66.7)1 (16.7)1 (33.3)4 (26.7) Abdominal pain1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3) Stomatitis0 (0.0)1 (33.3)0 (0.0)0 (0.0)1 (6.7)Investigations0 (0.0)0 (0.0)3 (50.0)1 (33.3)4 (26.7) Lipase increasedc0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3) Amylase increased0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Blood CPK increasedd0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Neutrophil count decreased0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)General disorders and administration site conditions0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3) Fatigue0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Pyrexia0 (0.0)0 (0.0)0 (0.0)1 (33.3)1 (6.7)Skin and subcutaneous tissue disorders1 (33.3)0 (0.0)1 (16.7)0 (0.0)2 (13.3) Pruritus1 (33.3)0 (0.0)1 (16.7)0 (0.0)2 (13.3)Values are n (%).bd, twice daily; CPK, creatine phosphokinase; TEAE, treatment-emergent adverse event.aTEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment). All TEAEs were coded using MedDRA version 26.0.bRelated TEAEs were those recorded on the adverse event (AE) electronic case report form page with a relationship to muvadenant listed as yes, unknown or missing.cA muvadenant-related grade 3 TEAE of lipase increased was reported in one patient in the 600-mg cohort; this patient also had a concurrent grade 1 AE of amylase increased.dA muvadenant-related grade 4 TEAE of blood CPK increased was reported in one patient in the 450-mg cohort. Both of these muvadenant-related TEAEs were assessed as dose-limiting toxicities. Table 4Muvadenant-related TEAEsSystem organ class preferred termaMuvadenant monotherapy (bd)150 mg (n = 3)300 mg (n = 3)450 mg (n = 6)600 mg (n = 3)Total (N = 15)Patients with ≥1 muvadenant-related TEAEb2 (66.7)3 (100.0)4 (66.7)1 (33.3)10 (66.7)Eye disorders1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7) Retinal degeneration1 (33.3)0 (0.0)0 (0.0)0 (0.0)1 (6.7)Gastrointestinal disorders1 (33.3)3 (100.0)1 (16.7)1 (33.3)6 (40.0) Nausea0 (0.0)2 (66.7)1 (16.7)1 (33.3)4 (26.7) Abdominal pain1 (33.3)0 (0.0)0 (0.0)1 (33.3)2 (13.3) Stomatitis0 (0.0)1 (33.3)0 (0.0)0 (0.0)1 (6.7)Investigations0 (0.0)0 (0.0)3 (50.0)1 (33.3)4 (26.7) Lipase increasedc0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3) Amylase increased0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Blood CPK increasedd0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Neutrophil count decreased0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7)General disorders and administration site conditions0 (0.0)0 (0.0)1 (16.7)1 (33.3)2 (13.3) Fatigue0 (0.0)0 (0.0)1 (16.7)0 (0.0)1 (6.7) Pyrexia0 (0.0)0 (0.0)0 (0.0)1 (33.3)1 (6.7)Skin and subcutaneous tissue disorders1 (33.3)0 (0.0)1 (16.7)0 (0.0)2 (13.3) Pruritus1 (33.3)0 (0.0)1 (16.7)0 (0.0)2 (13.3)Values are n (%).bd, twice daily; CPK, creatine phosphokinase; TEAE, treatment-emergent adverse event.aTEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment). All TEAEs were coded using MedDRA version 26.0.bRelated TEAEs were those recorded on the adverse event (AE) electronic case report form page with a relationship to muvadenant listed as yes, unknown or missing.cA muvadenant-related grade 3 TEAE of lipase increased was reported in one patient in the 600-mg cohort; this patient also had a concurrent grade 1 AE of amylase increased.dA muvadenant-related grade 4 TEAE of blood CPK increased was reported in one patient in the 450-mg cohort. Both of these muvadenant-related TEAEs were assessed as dose-limiting toxicities. Muvadenant-related TEAEs Values are n (%). bd, twice daily; CPK, creatine phosphokinase; TEAE, treatment-emergent adverse event. TEAEs were defined as events with an onset date or worsening during the on-treatment period (up to 30 days after the last dose of treatment). All TEAEs were coded using MedDRA version 26.0. Related TEAEs were those recorded on the adverse event (AE) electronic case report form page with a relationship to muvadenant listed as yes, unknown or missing. A muvadenant-related grade 3 TEAE of lipase increased was reported in one patient in the 600-mg cohort; this patient also had a concurrent grade 1 AE of amylase increased. A muvadenant-related grade 4 TEAE of blood CPK increased was reported in one patient in the 450-mg cohort. Both of these muvadenant-related TEAEs were assessed as dose-limiting toxicities. Serious TEAEs were reported in three patients (20.0%) across DLs and all required treatment interruption during the event; however, none were considered related to muvadenant. One patient in the 150-mg DL experienced a grade 3 cerebrovascular accident and two patients in the 300-mg DL experienced grade 3 groin pain and grade 3 retroperitoneal hemorrhage (n = 1 each). Permanent treatment withdrawal due to AEs was reported only in one patient in the 600-mg DL who experienced muvadenant-related, nonserious, grade 2 pyrexia, grade 2 nausea, grade 3 lipase increased and grade 2 abdominal pain. In one patient in the 450-mg DL, a nonserious muvadenant-related grade 3 event of blood creatinine phosphokinase increased required treatment interruption. The event worsened to grade 4 and was designated as a DLT. Following resolution, muvadenant was reinitiated at a reduced dose of 300 mg, after which creatinine phosphokinase remained normal. Two TEAEs related to eye disorders were reported, both classified as nonserious grade 1 retinal degeneration (assessed based on decrease in retinal thickness in optical coherence tomography) in patients in the 150-mg DL. In both patients, no symptoms of visual disturbances or blurred vision were observed. While one event was deemed muvadenant-related event and ongoing at the last follow-up (one month after the event onset), the other was not related to muvadenant and resolved after treatment interruption, with both events showing no impact on best-corrected visual acuity. In effect, no relevant AESIs were reported. However, the relatively small number of patients within each DL warrants caution when interpreting the results. Overall, two patients (13.3%) died during the study, and both deaths were attributed to disease progression >30 days after the last muvadenant dose. Clinical activity No patient achieved a confirmed or unconfirmed objective response (Figure 1). SD as the best overall response was recorded in three patients (Figure 1A and B) and included one patient with SD of 12.6 months at the 150-mg DL (primary thymic tumor) (Figure 1A). This patient had received only one prior treatment line with carboplatin plus etoposide for locally advanced/metastatic thymic tumor between September 2020 and March 2021, ∼23 months before entering this study. This suggests a possible slow progression of the tumor; however, as no previous tumor imaging was available, this could not be confirmed.Figure 1Clinical efficacy of muvadenant. (A) Time to and duration of confirmed response (investigator-assessed per RECIST v1.1). Swimmer plot detailing time on treatment and response assessments for patients. The length of each bar represents the time from treatment initiation to the date the patient was last known to be alive. Three patients had an initial assessment of SD earlier than 6 weeks after the first dose of muvadenant, followed by a second assessment of Pd. Therefore, these patients were assigned a BOR of Pd. (B) Best change from baseline in sum of diameters. Waterfall plot showing the best percentage change in the sum of tumor diameters from baseline. Note: Only patients with measurable baseline and after baseline tumor assessments were included.bd, twice daily; BOR, best overall response; NE, not evaluable; Pd, progressive disease; SD, stable disease. Clinical efficacy of muvadenant. (A) Time to and duration of confirmed response (investigator-assessed per RECIST v1.1). Swimmer plot detailing time on treatment and response assessments for patients. The length of each bar represents the time from treatment initiation to the date the patient was last known to be alive. Three patients had an initial assessment of SD earlier than 6 weeks after the first dose of muvadenant, followed by a second assessment of Pd. Therefore, these patients were assigned a BOR of Pd. (B) Best change from baseline in sum of diameters. Waterfall plot showing the best percentage change in the sum of tumor diameters from baseline. Note: Only patients with measurable baseline and after baseline tumor assessments were included. bd, twice daily; BOR, best overall response; NE, not evaluable; Pd, progressive disease; SD, stable disease. As there were no confirmed responses, DoR could not be determined. Across DLs, the median PFS was 1.3 months [95% confidence interval (CI) 1.2-2.6 months], with an estimated PFS rate of 20.0% (95% CI 0.0% to 40.2%) at 3 months. The PFS rate, based on the data for one patient with SD, was 10.0% (95% CI 0.0% to 27.2%) at each of the time points assessed (6, 9 and 12 months). Pharmacokinetic profile Muvadenant showed fast absorption after administration, with Tmax observed at ∼1.5-2 hours (Supplementary Figure S2, available at https://doi.org/10.1016/j.esmoop.2026.106962). Mean muvadenant concentrations generally increased with the DL on cycle 1 day 1 (C1D1) and on C1D8 and were modestly higher on C1D8 than those on C1D1, although there was considerable overlap of concentrations between DLs, particularly at earlier time points (Supplementary Figure S2, available at https://doi.org/10.1016/j.esmoop.2026.106962). Muvadenant PK exposure [Cmax and area under the curve (AUC)0-tlast] increased in a less than dose-proportional manner over the 150- to 600-mg dose range on C1D1 (Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2026.106962). Half-life was not identifiable in most patients due to the limited number of data points in the terminal phase. Mean accumulation ratios of ∼1.4-1.5 on C1D8 suggest only modest accumulation following bd dosing (Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2026.106962). The bd dosing interval and the expected long terminal half-life led to limited coverage of the elimination phase of muvadenant on both C1D1 and C1D8, thereby precluding reliable estimation of λz for a majority of PK profiles, and consequently, of λz-related parameters [e.g. t1/2, AUC0-∞, AUC0-∞/D, AUCꞇ, AUCꞇ/D, CL/F, Vz/F, LI and Racc(AUCꞇ)]. Results of an exploratory statistical analysis of dose proportionality using the Power model29 also predicted the observed less-than-proportional exposure profile of muvadenant, as slope estimates were below unity for both Cmax (0.466; 90% CI 0.047-0.884) and AUC0-tlast (0.669; 90% CI 0.310-0.1028) on C1D1. The results from this model on C1D8 should be interpreted with caution because of the limited amount of evaluable data (n < 3 for the 150-mg and 300-mg DLs; these were not included in the analysis). The observed less-than-proportional PK of muvadenant could be attributed to several factors. Firstly, PK data were collected only up to 8 hours after dosing, leading to significant extrapolation (>20%) in the AUC0-∞ calculation, which may have impacted the assessment of dose proportionality. Variability in absorption is also evident, as indicated by the shifting Tmax across DLs, potentially affecting Cmax evaluations. Secondly, muvadenant acts as both a substrate and an inducer of CYP3A4. This dose-dependent autoinduction of CYP3A4 may intensify at higher doses, contributing to the less-than-proportional PK. Lastly, while preclinical modeling suggests no absorption saturation up to 1000 mg, the possibility of saturation during this first-in-human trial cannot be excluded. PD profile Evaluable PD biomarker data to determine the change from baseline in pCREB levels following treatment with muvadenant were available only for one patient (300-mg DL). Data availability and evaluability were negatively impacted by a high attrition rate due to low peripheral lymphocyte counts and limited or absent stimulation of a nonselective A2AR agonist (5'-N-ethylcarboxamidoadenosine) in baseline samples (robust inhibition seen on C1D1 in only one sample). Therefore, target engagement and PD biomarker modulation with muvadenant could not be robustly demonstrated because of insufficient evaluable data, precluding conclusions about the relationship between pCREB levels and muvadenant PK. To better assess receptor coverage in this study, we extrapolated the IC50 values for muvadenant at the A2A and A2B receptors from in vitro studies using primary human T cells and myeloid cells and compared these values with the steady-state free plasma concentrations observed in this first-in-human study (Supplementary Figure S2, available at https://doi.org/10.1016/j.esmoop.2026.106962). This analysis indicated that the mean plasma concentrations of muvadenant exceeded the extrapolated IC50 values across the PK sampling period. RDE and MTD Based on all available data, the SMC recommended the 450-mg bd DL as the potential RDE; however, additional cohorts to confirm the RDE were not conducted because the study was closed early by the sponsor. An MTD was not declared by the SMC because, at the highest DL tested (600 mg), neither the criteria from the BLRM nor the requirement to treat six patients at the suggested MTD DL were fulfilled. Discussion Muvadenant monotherapy was generally well tolerated and a potential RDE of 450-mg bd was identified; however, additional confirmatory cohorts were not conducted due to the early closure of the study. Overall, the TEAE profile of muvadenant was manageable and similar across the DLs studied. There was no discernible pattern of muvadenant dose-dependent effects on the proportions of patients with TEAEs or serious TEAEs; however, the small number of patients at each DL precludes definitive conclusions. The reason for the early closure of the study was primarily driven by strategic considerations, including the evolving competitive landscape in immunotherapeutics. Multiple approaches to block protumorigenic adenosine signaling have been explored across various tumor types. Strategies include selective A2A receptor antagonism (taminadenant,16 ciforadenant,30 imaradenant,17,31,32 inupadenant33) and targeting enzymes that accumulate adenosine (such as anti-CD73, anti-CD38 and anti-CD39).7 Response rates have varied across studies, with A2A receptor antagonists as monotherapy yielding modest objective response rates of <10%.34 Their combination with other therapies has also been explored; however, consistent benefits across tumor types are yet to be observed. For example, a phase I study in patients with renal cell carcinoma (N = 68; 72% resistant or refractory to ICIs) showed that ciforadenant monotherapy (n = 33) yielded a PR rate of 3% compared with 11% for the combination of ciforadenant with atezolizumab (n = 35).30 On the contrary, in a phase I/Ib study in patients with advanced non-small-cell lung cancer (NSCLC; N = 50; 76% patients had received prior ICIs), taminadenant monotherapy (n = 25) achieved an overall response rate of 9.5%, compared with 8.3% for the combination of taminadenant and spartalizumab (n = 25).16 Recent studies have also explored A2B receptor antagonism, combinations of A2A and A2B receptor blockade and dual A2A/A2B antagonists.35, 36, 37, 38 Initial data from the first-in-class A2BR-selective antagonist PBF-1129 showed limited clinical activity as monotherapy in patients with metastatic NSCLC.35 The exploration of A2AR/A2BR dual antagonists in the phase I study of etrumadenant (AB928), in combination with chemotherapy or AB122 (anti-PD-1), in patients with advanced malignancies led to a disease control rate of 43% (12/28 patients).39 Subsequent results from ARC-9, a phase Ib/II trial evaluating the safety and efficacy of etrumadenant combination therapy [included zimberelimab (anti-PD-1 antibody) and FOLFOX/bevacizumab regimens or novel therapies; n = 75] against regorafenib (n = 37) in patients with metastatic colorectal cancer (mCRC), indicated clinically meaningful improvements in efficacy parameters: a median PFS of 6.2 versus 2.1 months and a median overall survival of 19.7 versus 9.5 months, with a 63% reduction in the risk of death in third-line mCRC.37 However, despite these positive early findings, no phase III studies are currently ongoing for etrumadenant combination therapy in mCRC and predictive biomarkers that could identify patients most likely to benefit from adenosine pathway blockade, either as monotherapy or in combination with checkpoint inhibitors, remain to be determined.13 In our study, which included unselected patients with pretreated advanced solid tumors, muvadenant monotherapy did not demonstrate antitumor activity. The best overall response was SD in three patients, including one patient with an SD duration of 12.6 months (primary thymic tumor). Given the significant time elapsed between the previous treatment and study entry, this SD likely reflects an indolent disease biology. It is important to note that most patients were heavily pretreated and had experienced disease progression following multiple lines of prior therapy, including immunotherapy with ICIs. Moreover, despite the majority of enrolled patients having tumor types that are not typically sensitive to ICIs, several had received prior ICIs, which may have also influenced tumor biology and the TME. The heterogeneity of primary tumor types in our study population may also partially explain the observed limited activity of muvadenant. Adenosine levels differ by tumor type, with extracellular adenosine levels varying from <1 μmol/L in kidney tumors to ∼10+ μmol/L (on average) in NSCLC; squamous cell carcinoma of the head and neck; and colon and pancreatic tumors, which can also contribute to differences in efficacy.15,40 As muvadenant was designed to protect immune cells from the immune cell–suppressive adenosine, especially at high concentrations, the patients enrolled in this trial were not preselected based on the levels of adenosine (or CD73 as a surrogate marker of adenosine accumulation, as used in preclinical studies).15 Therefore, testing of the drug in patients with potentially low tumor adenosine levels may have also contributed to the limited responses to muvadenant. Additional studies with larger patient populations are needed to determine whether certain cancer subtypes could benefit from dual A2A/A2B receptor antagonist-based therapy.16,39,41 The tolerability profile of muvadenant was generally comparable with that of the other two clinical stage dual A2A/A2B antagonists, etrumadenant and MK-1088, with no treatment-related severe AEs or deaths.37,38 In the randomized phase I study of MK-1088 in healthy volunteers, the most common TRAEs were insomnia (38%), dysgeusia (25%), blurred vision (13%) and headache (13%).38 No visual disturbances or blurred vision were observed with muvadenant in our study. Muvadenant showed relatively fast absorption after administration and only modest accumulation after multiple dosing. However, muvadenant exposure increased in a less than dose-proportional manner, which could be attributed to saturated absorption and combined effects of muvadenant being a substrate of CYP3A4, a direct and time-dependent CYP3A4 inhibitor, and a CYP3A4 inducer. Although the pCREB analysis in the present study was consistent with the predicted mechanism of action of muvadenant, it could not be correlated with clinical response due to paucity of viable samples and the lack of observed clinical responses. It is also important to note that the assessment of pCREB inhibition in T cells as the PD assay had limitations. Although it reflects antagonistic activity of muvadenant on A2A adenosine receptors, it is likely that it does not fully demonstrate activity of the drug on A2B adenosine receptors, which is more pronounced on myeloid cells. The lack of an A2B-specific PD assay in the study limits the predictive value of pCREB assay. However, our analysis of expected target coverage based on the peripheral PK or exposure data and IC50 values for muvadenant on A2A and A2B receptors extrapolated from our in vitro studies with primary human T cells and myeloid cells shows that muvadenant plasma concentrations were above those values. In summary, twice-daily oral muvadenant monotherapy was generally well tolerated in a population of unselected patients with pretreated advanced solid tumors. However, antitumor activity could not be established. Early study closure and the limited number of patients at each DL preclude meaningful interpretation of dose–effect relationships.